The Global Anti CD47 Drugs Market is driven by rising cancer prevalence
The Anti CD47 Drugs market refers to drugs that target CD47, a protein that is overexpressed in several cancers. CD47 acts as a "don't eat me" signal to macrophages and is involved in evading the immune system. Anti-CD47 drugs work by blocking this protein and enabling macrophages to phagocytose cancer cells. Some key players developing anti-CD47 drugs include Bristol Myers Squibb, Abbvie, C4 Therapeutics, Shanghai Junshi Biosciences, Arch Oncology, and Forte Biosciences. These drugs have shown promising results in clinical trials for hematologic as well as solid tumors. The anti-CD47 drug mechanism overrides the “don’t eat me” signal of cancer cells, marking them for destruction by macrophages.
The anti CD47 drugs market is estimated to be valued at USD 0.14 Bn in 2024 and is expected to reach USD 1.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 42.9% from 2024 to 2031.
The demand for Anti CD47 Drugs Market is growing rapidly due to the rising prevalence of cancer worldwide. According to GLOBOCAN 2020, there were an estimated 19.3 million new cancer cases and 10 million cancer deaths in 2020. Unmet needs in cancer treatment are providing a strong impetus to the development of novel drugs like anti-CD47 antibodies.
Get More Insights On- Anti CD47 Drugs Market
Get this Report in Japanese Language: 抗CD47薬市場
Get this Report in Korean Language: 항 CD47 약물 시장
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian